A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered day 1 and 15 every four weeks, in patients with advanced solid tumours

被引：0
|
作者：
Scheulen, M. [1 ]
Mross, K. [2 ]
Richly, H. [1 ]
Nokay, B. [1 ]
Frost, A. [2 ]
Scharr, D. [2 ]
Lee, K. H. [3 ]
Saunders, O. [3 ]
Hilbert, J. [4 ]
Fietz, O. [3 ]
机构：
[1] Univ Essen Gesamthsch, W German Canc Ctr, Innere Klin Tumorforsch, Essen, Germany
[2] Univ Freiburg, Tumour Biol Ctr, Freiburg, Germany
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Clin Res, Biberach, Germany
[4] Boehringer Ingelheim Pharmaceut Inc, Clin Pharmacokinet Pharmacodynam, Ridgefield, CT USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72203-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：158 / 159
页数：2
相关论文
共 50 条
  • [41] A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours
    Hirte, H
    Goel, R
    Major, P
    Seymour, L
    Huan, S
    Stewart, D
    Yau, J
    Arnold, A
    Holohan, S
    Waterfield, B
    Bates, S
    Bennett, K
    Walsh, W
    Elias, I
    ANNALS OF ONCOLOGY, 2000, 11 (12) : 1579 - 1584
  • [42] Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
    Cao, Junning
    Ji, Dongmei
    Chen, Zhiyu
    Shen, Weina
    Wang, Jin
    Li, Baoyue
    Chi, Haidong
    Long, Amanda
    Gao, Ling
    Li, Jin
    ONCOLOGIST, 2017, 22 (06): : 638 - +
  • [43] Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies
    Rixe, Olivier
    Puzanov, Igor
    LoRusso, Patricia M.
    Cohen, Roger B.
    Morris, John C.
    Olowokure, Olugbenga O.
    Yin, Jian Y.
    Doroumian, Severine
    Shen, Liji
    Olszanski, Anthony J.
    ANTI-CANCER DRUGS, 2015, 26 (07) : 785 - 792
  • [44] A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours
    Xiaoyu Li
    Meng Qiu
    ShengJun Wang
    Hong Zhu
    Bi Feng
    Li Zheng
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 593 - 604
  • [45] Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours
    Kitzen, J. J. E. M.
    de Jonge, M. J. A.
    Lamers, C. H. J.
    Eskens, F. A. L. M.
    van der Biessen, D.
    van Doorn, L.
    ter Steeg, J.
    Brandely, M.
    Puozzo, Ch.
    Verweij, J.
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (10) : 1764 - 1772
  • [46] Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
    Demetri, George D.
    Lo Russo, Patricia
    MacPherson, Lain R. J.
    Wang, Ding
    Morgan, Jeffrey A.
    Brunton, Valerie G.
    Paliwal, Prashni
    Agrawal, Shruti
    Voi, Maurizio
    Evan, T. R. Jeffry
    CLINICAL CANCER RESEARCH, 2009, 15 (19) : 6232 - 6240
  • [47] An intersubject dose-escalation study of tesetaxel administered orally once every 3 weeks and once weekly for 3 consecutive weeks in patients with advanced or metastatic solid tumors
    Beeram, M.
    Novick, S. C.
    Qureshi, A.
    Patnaik, A.
    Papadopoulos, K.
    Tolcher, A. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours
    Nobuyuki Yamamoto
    Narikazu Boku
    Hironobu Minami
    Cancer Chemotherapy and Pharmacology, 2009, 65 : 129 - 136
  • [49] A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours
    Christophe Le Tourneau
    Jean-Pierre Delord
    Nuria Kotecki
    Edith Borcoman
    Carlos Gomez-Roca
    Ségolène Hescot
    Christiane Jungels
    Anne Vincent-Salomon
    Vincent Cockenpot
    Lauriane Eberst
    Audrey Molé
    Wael Jdey
    Françoise Bono
    Véronique Trochon-Joseph
    Hélène Toussaint
    Christelle Zandanel
    Olga Adamiec
    Olivier de Beaumont
    Philippe Alexandre Cassier
    British Journal of Cancer, 2020, 123 : 1481 - 1489
  • [50] Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours
    Yamamoto, Nobuyuki
    Boku, Narikazu
    Minami, Hironobu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 65 (01) : 129 - 136
12345